In contrast, <i>TP53</i>-mutated AML remains a therapeutic challenge: although hypomethylating-agent/venetoclax-based regimens yield improved initial responses, remissions are generally short-lived and overall survival remains poor. The gene discussed is TP53; the disease is acute myeloid leukemia.